Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Irene M. Ghobrial"'
Autor:
Gullu Gorgun, Michelle E. Maglio, Cindy Varga, Constantine S. Mitsiades, Irene M. Ghobrial, Noopur Raje, Anna Guidetti, Mary McKenney, Robert L. Schlossman, Claudia Paba Prada, Paul G. Richardson, Kenneth C. Anderson, Nikhil C. Munshi, Teru Hideshima, Deborah Doss, Jacob P. Laubach
Publikováno v:
Expert Opinion on Orphan Drugs. 2:1089-1108
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is uniq
Autor:
Yivan Jiang, Brianna Berrios, P. Peter Ghoroghchian, Michael P. Agius, Alexandre Detappe, Irene M. Ghobrial, Jeremiah A. Johnson, Clelia Mathieu, Oksana Zavidij, Yujia Shen, Hung V. Nguyen
Publikováno v:
Blood. 132:4681-4681
Introduction. Synergistic delivery of free drugs is highly challenging due to each drug's unique pharmacokinetics and biodistribution profiles. The standard of care Bortezomib, Pomalidomide/Lenalidomide, and Dexamethasone only demonstrates synergy in
Autor:
Constantine S. Mitsiades, Mary McKenney, Teru Hideshima, Katherine Redman, Robert L. Schlossman, Paul G. Richardson, Kathleen Colson, Diane Warren, Irene M. Ghobrial, Laura E. Lunde, Nikhil C. Munshi, Kimberly Noonan, Deborah Doss, Kenneth C. Anderson, Jacob P. Laubach
Publikováno v:
European Journal of Haematology. 88:446-449
We present the case of a woman with relapsed multiple myeloma (MM) who received combination lenalidomide and bortezomib therapy for 90 cycles followed by continuous lenalidomide monotherapy and has completed over 100 cycles of treatment to date. The
Autor:
Irene M. Ghobrial, William S. Dalton, Dixie-Lee Esseltine, Amitabha Mazumder, Melissa Alsina, David Avigan, Paul G. Richardson, Robert L. Schlossman, Teru Hideshima, Carol Delaney, Diane Warren, Nikhil C. Munshi, Deborah Doss, Kenneth C. Anderson, Sundar Jagannath, Laura E. Lunde, Rob Knight, Constantine S. Mitsiades, Edie Weller, Mary McKenney
Publikováno v:
Journal of Clinical Oncology. 27:5713-5719
Purpose Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to bortezomib and dexamethasone. This phase I, dose-escalation study (ie, NCT00153933)
Autor:
Constantine S. Mitsiades, Nikhil C. Munshi, Robert L. Schlossman, Irene M. Ghobrial, Teru Hideshima, Paul G. Richardson, Kenneth C. Anderson
Publikováno v:
Expert review of anticancer therapy. 8(7)
Front-line therapy for multiple myeloma is rapidly evolving with the development of new, highly active regimens based on novel agents such as bortezomib. Bortezomib-based regimens are demonstrating substantial efficacy both as induction prior to stem
Autor:
Rob Knight, KC Anderson, Dixie-Lee Esseltine, S. Lonial, Noopur Raje, M. Alsina, Sundar Jagannath, Andrzej Jakubowiak, Irene M. Ghobrial, Paul G. Richardson
Publikováno v:
Journal of Clinical Oncology. 27:8536-8536
8536 Background: Lenalidomide (Revlimid, Len), bortezomib (VELCADE, Bz; maximum tolerated dose [MTD] 15 mg/1.0 mg/m2) ± dexamethasone (Dex; 20–40 mg; RVD) was well tolerated in a phase I study in relapsed/refractory MM patients (pts), with 58% ≥
Autor:
David Avigan, Constantine Mitsiades, Noopur Raje, Robert L. Schlossman, Sundar Jagannath, M Lauria, Irene M. Ghobrial, Sagar Lonial, Robert Knight, NC Munshi, Laura E. Lunde, KC Anderson, David H. Vesole, Diane Warren, K Shea, S Kaster, Robin Joyce, P. G. Richardson, Carol Delaney, Teru Hideshima, Deborah Doss, Amitabha Mazumder, DL Esseltine, Andrzej Jakubowiak, R Lukas
Publikováno v:
Clinical Lymphoma and Myeloma. 9:S38
A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma PG Richardson,1 S Lonial,1 A Jakubowiak,2 S Jagannath,3 N Raje,4 D Avigan,5 IM Ghobrial,6 R Schlossman,6 A Mazumder,3 NC Munshi,6 D Vesole,7 R Joyce
Autor:
John J. Densmore, Andrzej Jakubowiak, Robert Birch, Aparna Krishnan, Peter Sportelli, I. C. Henderson, Irene M. Ghobrial, Tara Kendall, L. Gardner, Jeffrey L. Wolf, Kathleen Colson, Seema Singhal, J. Stephenson, J. F. Martin, Dixil Francis, L. Lai, Teru Hideshima, N. Obadike, KC Anderson, Paul G. Richardson, Jayesh Mehta, Kevin Sullivan, Sagar Lonial
Publikováno v:
Blood. 110:1164-1164
INTRODUCTION: Perifosine (peri) is an oral, novel synthetic alkylphospholipid, with multiple effects on signal transduction pathways, including inhibition of Akt and activation of JNK. In vitro studies showed that peri induces cytotoxicity in both MM